Trajan Scientific and Medical (Trajan) led a "Microscopy Photos with Smartphones" session featuring MiPlatform, on 7 November 2015, at a workshop hosted by the Histotechnology Society of NSW, Australia.
40 people participated in the microscopy session led by Alex Anderson, Regional Account Manager - Northern Area, Australia, Trajan Scientific and Medical.
The session included hands-on use of the MiPlatform to take smartphone photos and videos when viewing microscope slides. At the end of the day, one lucky winner received a free MiPlatform - Chandra Parajuli, from Douglass Hanly Moir Pathology.
The MiPlatform is compatible with any smartphone so ask your local Trajan contact for a demonstration and see how it can change the way you study microscope slides.
Photo: MiPlatform is a smartphone adapter which is quick and easy to setup on microscopes.
Photo: MiPlatform maintains microscope-like navigation to fully utilize the advantages of microscope slides.
Photo (Middle): Chandra Parajuli, from Douglass Hanly Moir Pathology zooming in on a microscope slide using his smartphone and MiPlatform.
In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies.
Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.